z-logo
open-access-imgOpen Access
Immobilized anticancer agents and metal nanoparticles in a matrix of gellan: achievements and prospects
Author(s) -
Zhanar A. Nurakhmetova,
Gulnur S. Tatykhanova,
Sarkyt Ye. Kudaibergenov
Publication year - 2020
Publication title -
habaršy - a̋l-farabi atyndag̣y k̦azak̦ memlekettik ụlttyk̦ universiteti. himiâ seriâsy/chemical bulletin of kazakh national university
Language(s) - English
Resource type - Journals
eISSN - 2312-7554
pISSN - 1563-0331
DOI - 10.15328/cb1169
Subject(s) - photothermal therapy , gellan gum , nanoparticle , context (archaeology) , nanotechnology , materials science , nanomedicine , chemistry , colloidal gold , combinatorial chemistry , paleontology , food science , biology
A review is devoted to recent achievements in development of anticancer drugs based on natural polysaccharide – gellan that possesses coil-helix conformational transition, sol-gel phase transition, thermo- and salt sensitivity. The characteristics of high- and low-acyl gellan are briefly given and the influence of mono- and multivalent metal ions on the gelation efficiency is described. The mucoadhesive properties of gellan and its modified derivatives are briefly considered in the context of application in pharmacy as oral, buccal, nasal, ophthalmologic, vaginal forms. The main attention is paid to anticancer drugs, gold and silver nanoparticles immobilized within gellan matrix by chemical bonds, physical adsorption and chemosorption. The state-of-the art and perspectives of development of plasmonic photothermal therapy of cancer cells that is one of the promising direction of nanomedicine in diagnosis and treatment of oncological diseases are highlighted. It is outlined that the further strategy of development and application of plasmonic photothermal therapy into clinical practice is due to selection of metal nanoparticles with optimal sizes, high concentration, low cytotoxicity and suitable optical characteristics.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here